Optimer Pharmaceuticals (OPTR) Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection
Tweet Send to a Friend
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the results from its North American Phase 3 clinical study of fidaxomicin in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
